SCHEMBL15613679

SCHEMBL15613679

C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4cccc(OCc5ccccc5)c4)cc3)c3c(N)ncnc32)C1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 13/20 0.84
▸ EGFR P00533 10/20 0.84
▸ BMX P51813 5/20 0.84
▸ ITK Q08881 4/20 0.84
▸ TEC P42680 3/20 0.84
▸ HCK P08631 3/20 0.84
▸ SRC P12931 3/20 0.84
▸ BLK P51451 3/20 0.84
▸ TXK P42681 2/20 0.84
▸ LYN P07948 2/20 0.84
▸ FGFR2 P21802 2/20 0.84
▸ NUDT5 Q9UKK9 2/20 0.84
▸ JAK3 P52333 2/20 0.84
▸ ERBB2 P04626 2/20 0.84
▸ RIPK2 O43353 1/20 0.84
▸ NR1I2 O75469 1/20 0.84
▸ SLC22A3 O75751 1/20 0.84
▸ LATS1 O95835 1/20 0.84
▸ NUDT14 O95848 1/20 0.84
▸ ABL1 P00519 1/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20548939 0.93 EGFR (0.83) BTKEGFRBMXITKTEC
SCHEMBL19097665 0.93 EGFR (0.83) BTKEGFRBMXITKTEC
Ibrutinib SCHEMBL2244870 0.91 BTK (1.00) BTKEGFRBMXITKTEC
Ibrutinib SCHEMBL201642 0.91 BTK (1.00) BTKEGFRBMXITKTEC
Ibrutinib SCHEMBL201641 0.91 BTK (1.00) BTKEGFRBMXITKTEC
Ibrutinib SCHEMBL2244865 0.91 BTK (1.00) BTKEGFRBMXITKTEC
Ibrutinib SCHEMBL201859 0.91 BTK (1.00) BTKEGFRBMXITKTEC
SCHEMBL15613464 0.91 BTK (0.73) BTKEGFRBMXITKTEC
SCHEMBL21428758 0.89 BTK (0.95) BTKEGFRBMXITKTEC
SCHEMBL15613539 0.89 BTK (0.75) BTKEGFRBMXITKTEC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
WO-2013177668-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2013-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK BTK 10/4885EGFR 521/4885BMX 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback